Optimizing glycemic control with insulin glargine

Diabetes Technology and Therapeutics

Volumn 5, Issue 3, 2003, Pages 471-473

  Williams, John B ^a  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; PIOGLITAZONE; REPAGLINIDE;

ADULT; CASE REPORT; CLINICAL FEATURE; DRUG CHOICE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYMPTOM; UNCONSCIOUSNESS;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OBESITY;

EID: 0038389043     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091503765692009     Document Type: Letter

References (7)

1. Glaser B, Cerasi E: Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. Diabetes Obes Metab 1999;1:67-74.
2. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-2148.
3. Levien TL, Baker DE, White JR Jr, Campbell RK: Insulin glargine: a new basal insulin. Ann Pharmacother 2002;36:1019-1027.
4. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-636.
5. Yki-Järvinen H, Dressler A, Ziemen M, for the HOE 901/3002 Study Group: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-1136.
6. Riddle MC, Rosenstock J: Treatment to target study: insulin glargine vs NPH insulin added to oral therapy of type 2 diabetes. Successful control with less nocturnal hypoglycemia [abstract 457-P]. Diabetes 2002;51 (Suppl 2):A113.
7. Rosenstock J, Riddle MC: Treatment to target study: timing and frequency of nocturnal hypoglycemia. The value of adding bedtime basal insulin glargine over NPH insulin in insulin-naÔve patients with type 2 diabetes on oral agents [abstract 1982-PO]. Diabetes 2002;51(Suppl 2):A482.